Drugs / ATG
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00176917 Background | May 1999 → May 2008 | alpha-mannosidosis, mucolipidosis type II, mucopolysaccharidosis type 1, mucopolysaccharidosis type 6 | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00176917 ↗ |
| Route | Intravenous | “ANTI-THYMOCYTE GLOBULIN IV via the Hickman line” NCT00176917 ↗ |